ASCO 2020: Roche's TIGIT monoantireactorandaandta and PD-L1 monoantigen Tecentriq combine to extend survival in patients with non-small cell lung cancer

The 2020 ASCO Conference Summary shows that the TIGIT targeting antibody tiragolumab and Tecentriq combination can improve objective remission and no progression survival compared to the use of PD-L1 monolithtozumab alone to treat non-small cell lung cancerblocking TIGIT and PD-L1 may co-activate T cells and enhance anti-tumor activity in NK cellsThis is the scientific basis for combined drug use by Tiragolumab and Tecentriqresults showed that after 5.6 months of tracking, tiragolumab and Tecentriq had 31.3 percent ORR, compared with 16.2 percent for TecentriqIn the trial of 135 patients, PFS was 5.4 months and 3.6 months, respectivelyin subgroups of patients with high tumor expression PD-L1 also yielded better resultsAmong these subjects, the ORR for the combination was 55.2%, compared with 17.2% for Tecentriq aloneRoche said the combination also has good tolerance, with a rate of 3 or higher adverse events similar to Tecentriq's single-drug treatment, without adding much side effectsRoche will certainly continue to invest in the program and conduct further research through two Phase 3 clinical trials (SKYSCRAPER-01 and SKYSRCAPER-02)SKYSCRAPER-01 IS COMPARING TIRAGOLUMAB/TECENTRIQ MONOTHERAPY WITH TECENTRIQ MONOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED PD-L1-POSITIVE NSCLC, WHILE SKYSCRAPER-02 IS COMPARING THE TRIJOINT THERAPY OF TIRAGOLUMAB/TECTECIQ AND CHEMOTHERAPY IN PATIENTS WITH WIDELY TREATED SMALL CELL LUNG CANCER (ES-SCLC) PATIENTS USING TECENTRIQ/CHEMOTHERAPY ALONE